Age-Related Vaccine Adjuvant Market is segmented by Type (Pathogen, Particulate, Adjuvant Emulsion, Combination, Others), By Application (Cancer, Infectious Diseases, Others), by Administration (Intradermal, Intranasal, Intramuscular, Oral, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Age-Related Vaccine Adjuvant Market Size
Age-Related Vaccine Adjuvant Market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2031, growing at a CAGR of 10.6% during the forecast period (2024-2031). An adjuvant is an ingredient in some vaccines that helps produce a potent immune response in people receiving the vaccine. In other words, adjuvants aid vaccines to work better.
Age-Related Vaccine Adjuvant Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Age-Related Vaccine Adjuvant Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. The Age-Related Vaccine Adjuvant Market in the United States and Canada produces the utmost share. Whereas the European Age-Related Vaccine Adjuvant Market is projected to continue its presence globally during the period of 2024-2031.
Age-Related Vaccine Adjuvant Market Scope
|
Metrics |
Details |
|
Market CAGR |
10.6% |
|
Segments Covered |
By Type, By Application, By Route of Administration, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Age-Related Vaccine Adjuvant Market Trends
Initiation of advanced vaccine adjuvant, new initiatives taken up by different organizations and the increasing prevalence of multiple chronic diseases are driving the age-related vaccine adjuvant market growth during the forecast period.
The initiatives by different organizations are expected to drive age-related vaccine adjuvant market growth during the forecast period.
The various initiatives from different organizations fuel the growth of the age-related vaccine adjuvant market in the forecast period. For instance, in March 2021, the United States Department of Health and Human Services (HHS) invested nearly USD 10 billion to increase access to vaccines and better help communities of color, rural, low-income, and other marginalized communities in response to COVID-19. Moreover, in 2021, the World Health Organization (WHO) recommended the RTS, S vaccine against malaria for broader use. Furthermore, in December 2021, the board of Gavi, the Vaccine Alliance (Gavi), provided funding for vaccine procurement, technical assistance for vaccine introduction, and other activities that will enable interested countries to apply for support to introduce the vaccine. The board’s decision provides funding through 2025 and commits Gavi to continue supporting vaccine rollout and use into the future. Thus, from the data mentioned above, it is anticipated that the various initiatives from different organizations will drive the global age-related vaccine adjuvant market growth during the forecast period.
The high developmental cost is hampering the global market growth.
However, limited operating revenue for research and development of novel drugs and high costs associated with the development and stringent regulations are expected to obstruct age-related vaccine adjuvant market growth during the forecast period.
COVID-19 Impact.
COVID-19 positively impacted the global age-related vaccine adjuvant market since, because of the urgent need to combat COVID-19, multiple SARS-CoV-2 vaccines were rapidly developed across various platforms, including mRNA-based, viral vector-based, inactivated, and subunit vaccines. Most inactivated and subunit vaccines contain adjuvants such as alum, the saponin Matrix-M, AS03, and CpG with alum, demonstrating good immunogenicity data among older adults. Novavax COVID-19 Vaccine, Adjuvanted, contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Therefore, leaving a positive impact on the global age-related vaccine adjuvant market growth.
Age-Related Vaccine Adjuvant Market Segment Analysis
Cancer age-related vaccine adjuvant are expected to dominate the market throughout the forecast period (2023-2030).
The cancer segment is expected to dominate the global age-related vaccine adjuvants market during the forecast period (2023-2030) since the incidence rates for overall cancer rise as age increases, from less than 25 incidences per 100,000 people in age groups below age 20 to about 350 per 100,000 people aged 45–49, to more than 1,000 per 100,000 people in age groups 60-year plus. Therefore, the adjuvant vaccine is the most promising strategy to potentiate immune responsiveness in elderly cancer patients, as numerous innate and adaptive immune systems defects have been indeed described in elderly individuals, such as defects on Dendritic Cells in elderly individuals. Furthermore, the clinical research on the cancer adjuvant vaccine is fueling the dominance of cancer over the global age-related adjuvant vaccine market. For instance, a Phase 1b Study for evaluation of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer in older adults, sponsored by Massachusetts General Hospital. Similarly, A phase 2 Safety and Efficacy Trial of Vaccine Boosting With Lethally Beamed Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Therapy of Pancreatic Adenocarcinoma in older adults, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is estimated to be completed by December 2022. Likewise, an Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) for High-Risk Stage III/IV Ovarian Cancer expected to be completed by June 2023 and is sponsored by Gradalis, Inc. Thus, from the above data mentioned it is anticipated that cancer will dominate the global age-related adjuvant vaccine market throughout the forecast period.
Age-Related Vaccine Adjuvant Market Geographical Share
The North American region holds the largest global age-related vaccine adjuvant market.
North America dominates the global age-related vaccine market. It is estimated to dominate the global age-related vaccine adjuvants market throughout the forecast period (2023-2030). Most of the key market players, such as Agenus, Avanti Polar Lipids, Invivogen, SPI Pharma, Novavax and OZ Biosciences, hold most of the market share based in the United States, ensuring the dominance of North America over the global age-related adjuvant vaccine market. Furthermore, the growing geriatric population in North America is fueling its dominance over the global age-related adjuvant market. For instance, as per the UN population, around 16.9 percent of the American population was 65 years old or above in 2020 and is anticipated to reach 22 percent by 2050. Thus, from the data mentioned, it is expected that North America will dominate the global age-related adjuvant vaccine market during the forecast period.
Age-Related Vaccine Adjuvant Market Competitive Landscape
The age-related vaccine adjuvant market is highly competitive, with many existing major players and small vendors. Major global age-related vaccine adjuvant markets include Agenus, Biological E Limited, Avanti Polar Lipids, Invivogen, GSK, Novartis/CSL, Brentagg, SPI Pharma, Novavax and OZ Biosciences. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the age-related vaccine adjuvant market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc.
GlaxoSmithKline plc
Overview:
GSK is a global biopharma company dealing with prescription and nonprescription products. GSK was founded on 27 December 2000 and had headquarters in Brentford, United Kingdom. GSK has 45+ subsidiaries which create its global presence.
Product Portfolio:
GlaxoSmithKline plc’s product portfolio for age-related vaccine adjuvant has Cervarix: It is a suspension for injection containing purified proteins for two types of human papillomavirus (types 16 and 18). It is available in vials or prefilled syringes. It is used in males and females from the age of 9 to protect against the following conditions caused by certain types of human papillomavirus (HPV).
The global age-related vaccine adjuvant market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
